Joong-Won Park

Durvalumab with or without Bevacizumab as Adjuvant Therapy for Patients with Hepatocellular Carcinoma at Risk of Recurrence After Curative Therapy: EMERALD-2

Purpose: Hepatic resection and ablation are standard of care for patients with hepatocellular carcinoma (HCC), but although potentially curative, the risk of recurrence is high (44%–79% a...

Joong-Won Park ;

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Jennifer J. Knox ;

Jiaqi Fan , MD;

Ann-Lii Cheng , MD, PhD;

Shethah Morgan ;

Jian Zhou , MD, PhD;

Sean Cleary ;

Norihiro Kokudo ;

10/21/2019

CIO 2020-22 Durvalumab±Bevacizumab As Adjuvant Therapy In HCC At Risk Of Recurrence After Curative Therapy: EMERALD-2

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Philip He ;

Jennifer J. Knox ;

Shethah Morgan ;

Jiaqi Fan , MD;

Gordon Cohen ;

Sean Cleary ;

Ann-Lii Cheng , MD, PhD;

Norihiro Kokudo ;

Jian Zhou , MD, PhD;

Joong-Won Park ;

07/23/2021

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Joong-Won Park

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products